Trametinib bulk supplier for pharma manufacturers

Trametinib 0.5 mg, 1 mg, 2 mg Suppliers & Bulk Manufacturers

Q: What is Trametinib made from?

Trametinib is a smallâmolecule MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes in the MAPK/ERK signaling pathway, which helps prevent cancer cells from multiplying.

Available Forms: Tablets

Available Strengths: 0.5 mg, 1 mg, 2 mg

Reference Brands: Mekinist (USA/EU)

Category: Oncology Cancer Care

Trametinib is a targeted cancer therapy that inhibits MEK1 and MEK2 enzymes in the MAPK/ERK pathway, helping to slow or stop the growth of cancer cells. It is primarily used for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations and can be combined with BRAF inhibitors for enhanced efficacy.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Trametinib — third party manufacturing & bulk supply

Trametinib 0.5 mg, 1 mg, 2 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Trametinib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Trametinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Trametinib →

Back to Listing

Frequently Asked Questions

Trametinib is used to treat certain cancers, including unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and in combination with other drugs for some non‑small cell lung cancers, thyroid cancer, certain solid tumors, and glioma with specific mutations.

Trametinib is a small‑molecule MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes in the MAPK/ERK signaling pathway, which helps prevent cancer cells from multiplying.

The trade names are Mekinist and Spexotras.

It is manufactured and marketed by the companies holding the global marketing rights, including Novartis under the trade name Mekinist.

The generic name is trametinib.

Brand names include Mekinist and Spexotras.

Trametinib is produced as an oral drug in pharmaceutical manufacturing facilities under standard regulatory practices, available as tablets or oral solution depending on patient needs.